This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Allos: Folotyn Survival Trend in Lung Cancer

WESTMINSTER, Colo. ( TheStreet) -- Allos Therapeutics' (ALTH) cancer drug Folotyn reduced the risk of death compared to OSI Pharmaceuticals' (OSIP) Tarceva in a mid-stage study involving patients with non-small cell lung cancer, the company announced Wednesday.

The improved survival favoring Folotyn over Tarceva was only a trend because the small study was underpowered and was not expected to produce statistically significant results.

Also Wednesday, Allos said sales of Folotyn as a treatment for peripheral T-cell lymohoma (PTCL) were $9 million in the quarter, a 10% improvement sequentially but below Street consensus estimates.

Allos shares were down 30 cents to $5.40 in pre-market trading.

Folotyn was approved late last year as a treatment for PTCL. Allos is also developing the drug in the much larger non-small cell lung cancer market, where it would potentially compete against OSI's Tarceva and Eli Lilly's Alimta.

In the phase II lung cancer study, Folotyn reduced the risk of death by 13% compared to Tarceva. The study was also designed to compare the efficacy of Folotyn to Tarceva in various subgroups of lung cancer patients.

In patients with non-squamous cell lung cancer, which comprises the largest subgroup of lung cancer patients, Folotyn demonstrated a 35% reduction in the risk of death compared to Tarceva. This subgroup is important because it's where OSI generated the bulk of Tarceva's $1.2 billion in 2009 worldwide sales.

In patients characterized as light smokers, Folotyn reduced the risk of death by 37% compared to Tarceva. Positive trends in overall survival were observed favoring Foltyn in all other patient subgroups except patients with squamous cell carcinoma and patients previously treated with Lilly's Alimta.

The $9 million in gross sales for Folotyn in the second quarter fell well below the consensus estimates of $11-12 million, which will likely exacerbate investor concerns that the market potential in PTCL is smaller than originally envisioned.

Net product sales and total revenue in the quarter totaled $7.9 million, which reflects fees paid to distributors and adjustments made for possible government rebates and chargebacks.

Overall, Allos reported a net loss of $20 million, or 19 cents a share, a penny better than the Street's consensus estimate.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Readers Also Like:

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,282.82 +16.83 0.10%
S&P 500 2,013.98 +2.62 0.13%
NASDAQ 4,584.5320 -8.8930 -0.19%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs